GBC puts Marinomed under review, price target under review

• GBC put Marinomed under review, suspending its buy rating and €51 price target set through Dec. 31, 2027.
• The call follows a new restructuring proceeding opened July 23, 2026, after Unither talks collapsed and earn-out payments failed to materialize.
• The Carragelose asset sale included €5 million upfront, with up to €15 million in earn-outs that had been expected to fund the prior restructuring plan.
• Liabilities were put at about €27.9 million, with a new proposed restructuring quota of 20% versus 30% previously.
• GBC said valuation hinges on potential claims against Unither, creditor approval, funding for the quota, with possible dilution or asset sales for shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marinomed Biotech AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_26286) on July 24, 2026, and is solely responsible for the information contained therein.